Both Elan and Biogen are pioneers in the study of this pathway. It was launched first in the U.S. in 1996 for the treatment of relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. These side effects usually go away within a day after the injection and occur less often as the treatment continues. Reference is made in particular to statements regarding the potential for Antegren as a therapeutic product. These statements are based on the companies' current beliefs and expectations as to such future outcomes.
Drug development involves a high degree of risk.
Success in early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Factors which could cause actual results to differ materially from the companies' current expectation include the risk that the product may not show therapeutic effect or an acceptable safety profile in subsequent trials or may not meet applicable regulatory standards, or that problems or delays may arise during clinical trials or in the course of the development, testing or manufacturing of the product as well as the other risks and uncertainties described from time to time in the companies' periodic reports filed with the Securities and Exchange Commission. Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy.